Heska - HSKA Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Heska in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HSKA shares.
View HSKA analyst ratings or view top-rated stocks.

4 analysts have issued 12 month price targets for Heska's shares. Their HSKA share price forecasts range from $119.00 to $165.00. On average, they anticipate the company's share price to reach $142.25 in the next year. This suggests a possible upside of 113.9% from the stock's current price.
View analysts price targets for HSKA or view top-rated stocks among Wall Street analysts.

Heska's stock was trading at $182.49 at the beginning of 2022. Since then, HSKA shares have decreased by 63.6% and is now trading at $66.51.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our HSKA earnings forecast.

Heska Co. (NASDAQ:HSKA) announced its earnings results on Thursday, November, 4th. The medical research company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of $0.04 by $0.23. The medical research company had revenue of $60.24 million for the quarter, compared to analyst estimates of $63.80 million. Heska had a positive trailing twelve-month return on equity of 0.09% and a negative net margin of 6.26%. Heska's revenue for the quarter was up 6.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.25) earnings per share.

Heska updated its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $266.43 million-$266.43 million, compared to the consensus revenue estimate of $272.89 million.

5 employees have rated Heska Chief Executive Officer Kevin S. Wilson on Glassdoor.com. Kevin S. Wilson has an approval rating of 57% among the company's employees. This puts Kevin S. Wilson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Heska investors own include Gilead Sciences (GILD), Exxon Mobil (XOM), Netflix (NFLX), Biogen (BIIB), AbbVie (ABBV), Amgen (AMGN), Broadcom (AVGO), Alibaba Group (BABA), Exelixis (EXEL) and Merck & Co., Inc. (MRK).

Heska trades on the NASDAQ under the ticker symbol "HSKA."

Heska's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (16.59%), Vanguard Group Inc. (6.55%), Fred Alger Management LLC (5.44%), State Street Corp (3.57%), Riverbridge Partners LLC (3.00%) and Grandeur Peak Global Advisors LLC (2.33%). Insiders that own company stock include Bonnie J Trowbridge, Catherine Grassman, Jason D Aroesty, Kevin S Wilson, Nancy Wisnewski and Sharon J Larson.
View institutional ownership trends.

Shares of HSKA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HSKA stock can currently be purchased for approximately $66.51.

Heska (NASDAQ:HSKA) has a market capitalization of $720.04 million and generates $253.74 million in revenue each year. The medical research company earns $-1,150,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis.

The company employs 655 workers across the globe.

Heska's mailing address is 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538. The official website for the company is www.heska.com. The medical research company can be reached via phone at (970) 493-7272, via email at investorrelations@heska.com, or via fax at 970-619-3003.